Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
格式: Artigo
語言:Inglês
出版: MDPI AG 2020-03-01
叢編:International Journal of Molecular Sciences
主題:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
在線閱讀:https://www.mdpi.com/1422-0067/21/7/2275
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍